According to the statistical analysis of Sinopharm China Biotech, the results of the interim analysis of the new coronavirus inactivated vaccine phase III clinical trial showed that the safety of the new coronavirus inactivated vaccine of Sinopharm China Bio Beijing Company is good after inoculation. After two injections of the immunization program, the vaccine group will be vaccinated All patients produced high-titer antibodies, the neutralizing antibody positive conversion rate was 99.52%, and the vaccine's protective efficacy against the disease caused by the new coronavirus infection (COVID-19) was 79.34%. The data results reached the relevant technical standards of the World Health Organization and the country. The ?Guiding Principles for Clinical Evaluation of New Coronavirus Preventive Vaccines (Trial)? issued by the Food and Drug Administration is required by relevant standards. At present, Sinopharm China Biotech Beijing has formally submitted a conditional listing application to the State Food and Drug Administration.